Tenderwize
Zurück zur Suche

Open-house rebate agreements for Tocilizumab

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Nov 05, 2026 · 69 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Tocilizumab, ATC L04AC07

52/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

52 / 100

Komplexität

58 / 100

Risikofaktoren

Paper submissions require two original signed copies and timely receipt of the originals by the 10th of the month after...

Participation is limited to pharmaceutical companies and requires a signed declaration of reliability.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Non-exclusive supply/rebate agreement for Tocilizumab, ATC L04AC07.
  • Open-house model with identical, non-individually negotiable contract terms.
Vollständige Zusammenfassung anzeigen

This is an open-house pharmaceutical supply arrangement for Tocilizumab (ATC L04AC07) offered by AOK Bayern. It is not a competitive award procedure in the usual sense: the buyer states that all interested pharmaceutical companies meeting the stated suitability requirement can join on identical, non-negotiable terms. The contract can start from 2025-01-01, runs until 2026-12-31, and applications can be submitted until 2026-11-05 11:00. No contract value is stated.

Risiken

Paper submissions require two original signed copies and timely receipt of the originals by the 10th of the month after...

Participation is limited to pharmaceutical companies and requires a signed declaration of reliability.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Submit a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
  • Submit the completed and signed contract and the completed and signed annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house rebate agreements for Tocilizumab

Single lot covering non-exclusive open-house rebate agreements for the pharmaceutical product Tocilizumab, ATC L04AC07. The lot is for supplies in Germany, with performance in Bavaria (DE212). The procedure is open-house, with no selection among bidders and identical contract terms for all eligible pharmaceutical companies. Lot information comes from structured data and the XML notice.

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Dec 2024 - Dec 2026

Kategorie

Pharmaceutical products

Frist

Deadline Nov 05, 2026

Vergabedetails

Veröffentlichungsdatum
17 Nov 2024
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
701022-2024

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30